A PMHNP orders pharmacogenomic testing for a 38-year-old patient with treatment-resistant depression to guide medication selection. The patient expresses concern that the test results could be used against her by her health insurance company to deny coverage or increase premiums. The PMHNP counsels the patient about protections under the Genetic Information Nondiscrimination Act (GINA). Which of the following is most accurate?